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and Pharmacokinetic Considerations 
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Abstract: Neuronal nitric oxide synthase (nNOS) produces the key signalling media-
tor nitric oxide, (NO). This gaseous, free radical molecule modulates a vast array of 
biological processes, from vascular pressure to immune responses and neurological 
signalling cascades. Overproduction of NO has been implicated in conditions includ-
ing Alzheimer’s disease, Parkinson’s disease and schizophrenia. Inhibition of nNOS 
therefore offers a potential therapeutic approach for treatment of these conditions. This endeavour is made more com-
plex by the fact that there are two other isoforms of nitric oxide synthase (NOS), endothelial NOS (eNOS) and induc-
ible NOS (iNOS). The selectivity of nNOS inhibitors is therefore a key concern for therapeutic development. This re-
view explores recent advances in the field of selective nNOS inhibition. A particular focus is placed on computational 
approaches towards the rational design of selective nNOS ligands with improved pharmacokinetic properties. These 
ligands have been targeted at four key binding sites of the nNOS enzyme - the tetrahydrobiopterin, calmodulin, nicoti-
namide adenine dinucleotide phosphate (NADPH) and arginine binding sites. The binding sites, and the compounds 
used to inhibit them, will be discussed in turn, along with the computational methods which have been employed in the 
field of nNOS inhibition.  
Keywords: Binding pockets, in silico, neuronal nitric oxide synthase (nNOS), selective inhibition. 
1. INTRODUCTION 
1.1. NOS Function 
Nitric oxide (NO) is a small, gaseous, free radical mole-
cule which acts as a vital secondary messenger for a variety 
of physiological functions. NO exerts its signalling effect by 
stimulation of the cyclic guanosine 3’,5’-monophosphate 
(cGMP) pathway, causing an increase in production of 
cGMP and activation of phosphorylation events [1-3]. cGMP 
signalling cascades have been directly linked to a plethora of 
neuronal and cardiovascular actions, including long term 
memory formation and vascular pressure regulation [4]. NO 
is also directly employed as a reactive oxygen species (ROS) 
to combat foreign pathogens and tumours [5].  
NO is produced by a family of enzymes called the nitric 
oxide synthases (NOS). These enzymes convert L-arginine 
and molecular oxygen to NO and L-citrulline via a N-
hydroxy-L-arginine (L-NOHA) intermediate (Fig. 1) [6]. 
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There are three mammalian isoforms of the enzyme. En-
dothelial NOS (eNOS), produces NO for use in the vascular 
system where it regulates vasodilation and vascular pressure 
[7]. eNOS has also been observed in the lungs and trachea 
where it modulates ciliary motility and smooth muscle re-
laxation [7]. Neuronal NOS (nNOS) is localized primarily in 
the brain and central nervous system (CNS). The NO pro-
duced by this isoform is used for neurogenesis and regulation 
of the cholinergic, dopaminergic and glutaminergic signal-
ling pathways, among others [8]. The final isoform, induc-
ible nitric oxide synthase (iNOS), produces NO in response 
to infection of host cells by bacteria or other pathogens. This 
NO has been observed to have both pro and anti-
inflammatory effects and also some tumour suppression ac-
tivity [9].  
All three isoforms exist as homodimeric enzymes, with 
each monomer consisting of an N-terminal oxygenase do-
main and a C-terminal reductase domain [10]. These do-
mains are connected by a calmodulin binding region (CBR). 
The oxygenase domain contains a non-catalytic zinc, tetra-
hydrobiopterin (BH4) and the catalytic active site, which 
binds L-arginine and a heme moiety. The reductase domain 
employs nicotinamide adenine dinucleotide phosphate 
(NADPH), flavin adenine dinucleotide (FAD) and flavin 
mononucleotide (FMN) to shuttle electrons from the reduc-
tase domain to the iron at the centre of the heme co-factor in 
the catalytic active site [6]. In the active site, L-arginine then 
Please provide 
corresponding author(s) 
photograph
size should be 4" x 4" inches
Please provide 
corresponding author(s) 
photograph
size should be 4" x 4" inches
2    Current Medicinal Chemistry, 2015, Vol. 22, No. 1 Curtin et al. 
NH2+H2N
NH
NH3+
HO
O-
NADPH + O2
NADP+ + H2O
NH2N
NH
NH3+
HO
O-
HO
NADPH + O2
1/2 NADP+ + H2O
NH2O
NH
NH3+
HO
O-
+ NO
L-arginine L-citrullineL-NOHA  
Fig. (1). Production of NO from L-arginine and molecular oxygen. 
 
becomes oxidised to L-citrulline and NO is produced [11]. 
The zinc ion in the oxygenase domain, while not directly 
participating in the catalytic cycle, provides a coordination 
site for four symmetry related cysteine residues, two from 
each monomer. This tetrahedral coordination sphere is an 
integral part of the dimer interface of NOS enzymes [12-14].  
Activation of eNOS and nNOS is dependent on 
calmodulin (CaM) binding [15]. This binding event is con-
trolled by calcium levels where an increase in cellular cal-
cium concentration facilitates formation of the NOS/CaM 
complex. Without CaM the enzymes are far less efficient at 
electron transfer and activity notably decreases [16]. This 
system offers a regulatory mechanism for the constitutively 
expressed eNOS and nNOS. In contrast, CaM is bound to 
iNOS, even at low calcium concentrations, and as this iso-
form is inducibly expressed, it is regulated at the transcrip-
tional level [17].  
The mechanism of NO production is conserved across all 
three isoforms with the heme iron in the arginine binding site 
playing a central role in the catalytic cycle. Although some 
of the specifics of this pathway have yet to be elucidated, a 
proposed cycle is provided below, adapted from the literature 
[17-19]. The exact nature of the oxidative species is still un-
clear [18].  
The proposed cycle begins with the heme iron in the rest-
ing (III) oxidation state. An electron, transferred from the 
reductase domain, reduces the heme iron to the (II) oxidation 
state. Molecular oxygen binds to the iron and subsequent 
electron transfer from BH4 and protonation generates an iron 
peroxy complex. Protonation, electron transfer (from the 
porphyrin (Por) ring) and loss of water generates the iron 
(IV) complex with a doubly bound oxygen atom [15, 18]. 
The iron (IV) complex then reacts with L -arginine to form 
the intermediate L-NOHA and iron (III) is regenerated. A 
similar sequence of steps is then repeated, starting with the 
transfer of an electron from the reductase domain, reducing 
the heme iron to the (II) oxidation state. The reaction se-
quence changes once the iron (III) peroxy species is gener-
ated, which reacts with L-NOHA to produce L-citrulline and 
an iron (III) nitrosyl species. In the final steps, the NO radi-
cal is formed and released along with the regeneration of 
iron (III) and the cycle begins again.  
1.2. NOS and Disease 
Uncoupling of the NOS electron transport chain, or over-
production of NO by the NOS enzymes, has been linked to a 
wide variety of neurological and physiological disorders 
[20,21]. In the absence of BH4 the NOS electron transport 
chain becomes uncoupled, which results in the production of 
ROS such as superoxide, O2-. This superoxide can further 
react to generate reactive nitrogen species (RNS), such as 
peroxynitrite (ONOO-) [11,19,22]. Both of these species can 
inflict oxidative stress on cells, resulting in translation errors 
and protein aggregation. This may occur with any of the 
NOS isoforms. In situations where the NOS enzyme is 
overly active, these oxidative stress events happen more rap-
idly resulting in accelerated cellular damage.  
Oxidative damage caused by iNOS generated NO has 
been linked to auto immune and inflammatory disorders in-
cluding rheumatoid arthritis [23]. Excessive NO production 
by iNOS is also a contributory factor in the onset of septic 
shock [9]. Over active nNOS can result in hyperphosphor-
lyation and accumulation of tau proteins, an event which has 
been implicated in Alzheimer’s disease [24,25]. In addition 
oxidative damage caused by over active nNOS leads to dys-
regulation of the signalling pathways and has long been as-
sociated with a variety of neurological conditions including 
Parkinson’s disease [26,27]. Elevated levels of NO metabo-
lites have also been observed in the brain tissue of schizo-
phrenic patients [28]. eNOS has not been directly identified 
as a “disease gene”, however oxidative damage potentially 
caused by overactive eNOS has been observed in a range of 
cardiovascular diseases [29]. 
1.3. NOS Binding Pockets and Ligand Design 
Partial inhibition of overactive NOS enzymes may slow 
the production of damaging ROS and RNS and prevent the 
build-up of potentially harmful levels of NO. To date several 
families of small molecule inhibitors have been developed 
for this purpose. These inhibitors have been targeted at four 
potential therapeutic target sites of the NOS enzymes. These 
are:  
1. The BH4 site, located in the oxygenase domain, which 
binds the co-factor BH4.  
2. The CaM binding site, which sits between the oxygenase 
and reductase domains.  
3. The NADPH binding site, which is located in the reduc-
tase domain. 
4. The catalytic active site, which is located in the oxy-
genase domain and binds arginine for production of NO.  
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These four sites have been exploited for the design of 
selective nNOS ligands using structure based drug design 
(SBDD) and ligand based drug design (LBDD) ap-
proaches. SBDD encompasses the use of techniques such 
as molecular docking to predict protein-ligand [30] interac-
tions, and de novo design of novel compounds. In contrast, 
LBDD focuses on available ligand based experimental in-
formation and includes techniques such as pharmacophore 
design and quantitative structure activity relationship 
(QSAR) approaches [31]. Both SBDD and LBDD have 
resulted in some notable successes in nNOS inhibitor de-
velopment with hit compounds displaying good levels of 
activity and selectivity. The pharmacokinetics (PK) proper-
ties and blood brain barrier (BBB) penetration of nNOS 
inhibitors is also of critical importance. The hit to lead 
process often focuses on examining the PK properties of a 
hit compound and employs computational and medicinal 
chemistry techniques that result in compounds with lower 
molecular weights, lower numbers of hydrogen bond (HB) 
donors/acceptors and increased lipophilicity. Some nNOS 
inhibitors which have shown promising efficacy and selec-
tivity have undergone structural modifications in order to 
improve their PK properties and make them more attractive 
for clinical use.  
Previous reviews in this area have focused on the me-
dicinal chemistry and SAR development of inhibitors for the 
three NOS isoforms [32,33]. This review will discuss the 
classes of inhibitors developed for each of the four nNOS 
therapeutic target sites, their potential interactions with the 
target site and the role computer aided drug design has 
played in the process of selective nNOS inhibition. The PK 
properties of some of the most efficacious nNOS inhibitors 
will also be examined.  
2. NOS BINDING SITES 
2.1. BH4 Binding Site 
Tetrahydrobiopterin, BH4 (Fig. 3), is a pterin ring con-
taining prosthetic group which is crucial for NOS function. It 
participates in electron transfer during NO production,  
(Fig. 2), and also plays a role in NOS dimer formation and 
stabilisation, which is necessary for enzyme activation [34]. 
Owing to the importance of the BH4 binding site in NOS 
enzymes, efforts have been made to target it using various 
substituted pterins. Matter et al. developed a series of 65 4-
amino pteridine and 4-oxo pteridines, and examined their 
inhibitory effects on recombinantly produced NOS protein 
[35-37].  
 
Fig. (2). Proposed NOS catalytic cycle (where Por=porphyrin). 
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Fig. (3). Tetrahydrobiopterin. 
 
In the absence, at the time, of any experimentally derived 
protein crystal structure for nNOS, Matter et al. made use of 
homology modelling to rationally develop these 65 inhibi-
tors. Murine iNOS and bovine eNOS [14,38] crystal struc-
tures were used as templates with a sequence homology to 
human nNOS of 52.19% and 57.34% respectively. Utilising 
their human nNOS homology model, Matter et al. [36] de-
veloped 3D-QSAR models, and performed comparative mo-
lecular field analysis (CoMFA) and comparative molecular 
similarity index analysis (CoMSIA) to correlate molecular 
property fields to biological activities. The models were de-
veloped to provide guidelines and activity predictions for 
novel nNOS inhibitors. The preferred model identified one 
large sterically favourable region matching with the require-
ment for pterin binding. A series of the predicted inhibitors 
were synthesised and tested.  
One of the most efficacious and selective compounds to 
result from this study was compound 1 (Fig. 4) Compound 1 
[36] had IC50 values of 5 µM, 214.2 µM and 31.7 µM for 
porcine nNOS, bovine eNOS and human iNOS, respectively. 
It was suggested that this selectivity was based on a one resi-
due difference between the isoforms. In eNOS residue 106 is 
a Val, whereas iNOS and nNOS contain Met in the equiva-
lent position. The added steric bulk of the valine residue in 
eNOS may make binding of compound 1 to eNOS less fa-
vourable than binding to either iNOS or nNOS. No explana-
tion was provided in this initial publication regarding com-
pound selectivity for nNOS over iNOS. 
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Fig. (4). Selective nNOS inhibitor, compound 1 [36]. 
 
In a subsequent publication, Matter et al. [37] presented 
the key interactions for BH4 in the crystallised rat nNOS BH4 
binding site (Fig. 5). The strongest interaction for BH4 was 
determined to occur with a tryptophan, Trp678. A π-π inter-
action was observed between this residue and BH4 at a dis-
tance of 3.6 Å. An extensive network of HB interactions was 
also identified. N-3 of BH4 forms a direct HB with the car-
boxylate of the heme moiety and a solvent mediated interac-
tion also exists between the same propionate group and the 
C-4 carbonyl. This carbonyl group directly HBs with 
Arg596. The primary amine at C-2 interacts with the heme 
propionate and HBs with Trp678. Matter et al. described the 
N-8 hydrogen interacting with Val677 and the BH4 dihy-
droxypropyl chain extending into the pocket formed by side 
chains of TrpB306, Met336 and TrpB676. The dihy-
droxypropyl chain also interacts with Ser334 and PheB691 
carbonyl oxygens and with HisB692 via structural water. 
 
 
Fig. (5). Rat nNOS BH4 binding site key residues (PDB: 4D2Y) 
with BH4 and heme. The structural water which mediates the dihy-
droxypropyl interaction with HisB692 has been included [37]. All 
images generated with Pymol [39]. 
 
With a clear and detailed knowledge of the key interac-
tions within the binding site, the group refined their previous 
inhibitor family and devised four key scaffolds (A1, A2, T1 
and T2), which attempted to mimic the interactions of BH4 
with the nNOS binding site (Fig. 6) [37]. 
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Fig. (6). Refined inhibitor scaffolds based on BH4 interactions with 
the rat nNOS binding site [37].  
 
A variety of compounds were developed based on these 
scaffolds which showed an array of selectivities and poten-
cies against nNOS [37]. The assay work was conducted us-
ing the human nNOS isoform. Once again compound 1  
(Fig. 4) proved to be both efficacious against, and selective 
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for, human nNOS. The IC50 for this compound against hu-
man nNOS was 3.68 µM with a 58.20 and 8.62 fold, selec-
tivity over human iNOS and human eNOS, respectively. 
Compound 1 was a member of the T1 scaffold family shown 
above (Fig. 6). 
The binding mode of compound 1 in the rat nNOS BH4 
site was predicted using docking [37]. The key predicted 
interactions for compound 1 were similar to the X-ray vali-
dated interactions of BH4 with the rat nNOS binding site. 
The primary amine group HBs to the heme carboxylate and 
also to the Trp678 residue. The hydrogen on N-8 interacts 
with Val677. The C-4 carbonyl of BH4 is replaced by a C-4 
NH, which breaks the HB interaction with Arg596. The large 
p-chlorophenyl group is accommodated by a pocket formed 
by TrpB306, Met336 TrpB676 and Glu694 (Fig. 5). This 
pocket plays a key role in the selectivity of compound 1 for 
nNOS over eNOS and iNOS. Replacement of Met336 with a 
valine (as in eNOS) resulted in lower binding affinity as pre-
viously suggested by Matter et al. [36]. 
The basis for NOS selectivity of the A1, A2, T1 and T2 
scaffolds (Fig. 6) was further explored and three key sub-
stituent groups were identified as having an impact on com-
pound selectivity [37]. These were: 
1. Bulky, hydrophobic substituents at R2 or R3 increased 
selectivity for nNOS over eNOS and iNOS on scaffold 
T1 and T2 
2. Substituted amines at R1 (scaffold A1 and T1), are pre-
ferred over oxo groups (scaffold A2 and T2) 
3. Hydrophobic electron rich groups at R3 increased bind-
ing for all scaffolds 
The work of Matter et al. established the BH4 binding 
site as a validated target site for selective nNOS inhibition. 
However, much of the subsequent literature has focused on 
other NOS binding sites.  
2.2. Calmodulin Binding Site 
CaM binding to NOS enzymes is an integral part of their 
function. The calmodulin binding region (CBR) of the en-
zymes is a ~25 amino acid sequence located between the 
oxygenase and reductase domain [40]. CaM binding allows a 
70 Å conformational change to occur in the NOS proteins, as 
determined by NMR spectroscopy and hydrogen deuterium 
exchange mass spectrometry [41,42]. This conformational 
change facilitates the transfer of an electron from the final 
reductase partner, FMN, to the heme moiety in the oxy-
genase domain of another NOS monomer as illustrated in the 
schematic (Fig. 7) [16].  
The interaction between the NOS proteins and CaM has 
been explored using crystallography and computational stud-
ies. Human eNOS binds to CaM using the classical 1-5-8-14 
motif [43,44] with Phe496, Ala500, Val503 and Leu509 of 
eNOS forming critical interactions with CaM [45]. The 
alignment of the three NOS calmodulin binding domains is 
shown below, with the 1-5-8-14 residue highlighted in each 
sequence (Table 1). The 1-5-8-14 residue motif is conserved 
precisely in human nNOS and eNOS, while there are two 
residue changes in the iNOS motif. The iNOS sequence con-
tains more hydrophobic residues than either of the constitu-
tive isoforms, which may explain the higher affinity of iNOS 
for CaM [45]. 
These CBRs of the NOS proteins have been suggested as 
a possible therapeutic target site for NOS inhibition [40,46-
48]. The residue differences between the nNOS CBR and the 
eNOS and iNOS CBR may make selective nNOS inhibition 
of this site possible. There are two principle strategies fo-
cused on CaM. The first is to design molecules that bind to 
CaM itself and prevent it binding to its recognition site on 
the NOS proteins. Some of the compounds tested for this 
purpose include the wasp venom peptide mastoparan, the bee 
venom peptide melittin and monobutyltin trichloride (com-
 
Fig. (7). CaM mediated hinge of NOS proteins. The NOS protein is shown in its dimer form, with one monomer in grey and the other in 
white. 
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pound 2, Fig. 8) [40]. These compounds were observed to 
decrease the levels of CaM available to nNOS in an isolated 
system, with Ki values of 5 nM, 3nM and 8µM for CaM re-
spectively. However, this method of NOS inhibition is not 
selective for nNOS as the compounds bind to CaM and not 
to the NOS enzymes themselves.  
 
Table 1. CaM binding regions of the human NOS isoforms 
with the 1-5-8-14 motif highlighted in bold. 
Isoform (Residues) Alignment 
Human iNOS (412-431) REIPLKVLVKAVLFACMLMR 
Human eNOS (493-512) RKKTFKEVANAVKISASLMG 
Human nNOS (732-751) RAIGFKKLAEAVKFSAKLMG 
 
O
N
Sn
Cl
ClCl
 
Fig. (8). Monobutyltin trichloride, compound 2 and Tamoxifen, 
compound 3.  
 
An alternative approach is to design an inhibitor which 
competitively binds to the CBR of the NOS proteins, thus 
preventing CaM binding. This method may be more favour-
able as it offers the possibility of selective nNOS inhibition 
and would also avoid interfering with other CaM signalling 
pathways not related to NOS. These pathways include many 
vital physiological functions such as muscle contractions, 
and therefore non-specific CaM inhibition may not be clini-
cally desirable. The breast cancer treatment Tamoxifen 
(compound 3, Fig. 8) was found to bind to the nNOS CBR 
with a reduction in enzyme activity in the range of 10-30% 
observed [40]. No selectivity data was presented in this pub-
lication.  
Some studies have also been conducted on NOS CaM in-
hibition using synthetic peptides which were 19-28 residues 
in length. These sequences were not computationally de-
signed but were observed to bind to the eNOS CBR and pre-
vented CaM from interacting with the eNOS enzyme, thus 
inhibiting NO production. [49] Other non-computationally 
derived compounds used to inhibit NOS/CaM interaction 
include compound 4 (Fig. 9) which was reported to have an 
IC50 of 1.99 µM against the CaM site of recombinant rat 
nNOS [50].  
The CBR of nNOS has not been as extensively studied as 
other pockets such as the arginine binding site for nNOS 
inhibition. One of the key challenges associated with target-
ing the CBR region of nNOS is generating significant iso-
form selectivity. In addition, the design of compounds to 
disrupt protein-protein interactions is also inherently difficult 
no matter what the target [51].  
 
Fig. (9). Competitive CaM inhibitor, compound 4 [50]. 
 
2.3. NADPH Binding Site 
NOS catalysis is driven by the reduction of NADPH, 
which binds to the reductase domain of NOS enzymes. The 
NADPH binding site therefore offers a potential intervention 
point at which the NOS catalytic cycle could be halted, thus 
inhibiting enzyme activity. Beaumont et al. [52] developed a 
nanotrigger, NT1, to monitor enzymatic activity at this site. 
NT1 contains a conjugated, photoactivatable chromophore 
substituted with two donor groups that replaced the 
nicotinamide moiety of NADPH (Fig. 10) [52-54]. This 
compound has the ability to initiate the redox reaction, 
triggered by a short laser pulse, leading to enzymatic activity 
with redox reaction. Subsequently, Beaumont et al. [54] 
assessed the selective binding of NT1 to nNOS using 
fluorescence measurements and molecular modelling. 
Molecular dynamic (MD) simulations revealed that the 
regulatory Phe1395 (rat nNOS) flipped away from FAD 
upon NT1 binding, bringing NT1 and FAD into close 
proximity. A number of HBs stabilised the NT1 interaction, 
including those between the terminal phosphate group and 
Arg1400, Arg1314, and Arg1284. The amide carbonyl 
oxygen formed a HB with Arg1010, while the terminal 
amino group interacted with Asp1393 and Ser1176. The 
authors proposed the use of NT1 for time resolved X-ray and 
other cellular applications including the design of specific 
activators or inhibitors of enzymatic activities. 
 
 
Fig. (10). Nanotrigger NT1 [52] and nanoshutter NS1 [55], com-
pound 5 and 6.  The structural motif on the right of the image binds 
to the NADPH site in NOS proteins, while the left portion of the 
compound acts as the chromophore. 
 
Subsequently, Li et al. [55] examined the use of a 
nanoshutter, NS1, (Fig. 10) which also targets the NADPH 
site of nNOS. Here a nucleotide moiety, mimicking NADPH, 
is linked to a conjugated push-pull chromophore with non-
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linear absorption properties. The development of NS1 was 
guided by molecular modelling studies which replaced the 
1,4-diaryl-butadiene moiety of NT1 with a stilbene moiety 
[55]. The authors proposed that employing a nitro group as 
the terminal electron acceptor would block electron flow and 
hence inhibit NOS activity. NS1 did indeed inhibit NOS ac-
tivity and was shown, using molecular docking and 10 ns 
MD simulations, to fit into the narrow NADPH site of 
nNOS. The key interactions across the simulation again in-
volved the conserved Arg residues (Arg1400, Arg1314, 
Arg1284, Arg1010) in the NADPH binding site. NS1 repre-
sents a new class of NOS inhibitor and, as a fluorescent 
compound with 2-photon excitation properties, NS1 has po-
tential for use in NOS imaging in living tissues when bound 
to constitutive eNOS or nNOS. 
2.4. Arginine Binding Site 
2.4.1. Guanidinium Containing Inhibitors 
A large portion of contemporary literature in the area of 
nNOS inhibition has focused on arginine analogues 
[32,56,57]. These compounds act as competitive inhibitors of 
the NOS isoforms by mimicking the interactions of the en-
zyme’s natural substrate. One of the first compounds devel-
oped in this area was Nω-nitro-L-arginine (L-NNA) Fig. (11). 
 
OH
O
N
H
N
H
O2N
NH
NH2  
Fig. (11). L-NNA (Compound 7), one of the earliest arginine mim-
ics studied for NOS inhibition [58]. 
 
L-NNA has a potent effect on eNOS resulting in severe 
hypertension and hence a number of derivatives based on L-
NNA were developed in order to improve selectivity for 
nNOS [59]. Modifications included replacing the carboxylic 
acid functionality with a methyl ester and substitution of the 
nitro group for a methyl group. However, these compounds 
continue to suffer from poor isoform selectivity and have 
pharmacokinetic properties which make them unattractive as 
potential therapeutics [60].  
In an attempt to improve the potential of the L-NNA class 
of NOS inhibitors, the precise binding mode of L-NNA with 
bovine eNOS was deduced via crystallization in 2001 [61]. It 
was observed that L-NNA retained the same HB pattern as 
the natural substrate, L-arginine, with HBs forming between 
the Glu363 and the guanidinium moiety and between the α-
amino group on the inhibitor and the heme propionate in the 
binding site. Thirteen non bonded interactions were observed 
between L-NNA and the binding site, all involving the nitro 
group and Pro336, Phe355, Ser356 and Gly357 (Fig. 12). 
The eNOS inhibition studies were the first step towards un-
derstanding the key binding elements necessary for selective 
nNOS inhibition using the L-NNA family of inhibitors. 
The vast majority of subsequent nNOS inhibition studies 
have been conducted using the rat isoform of nNOS [62,63] 
or on a homology model of the human nNOS based on the 
rat nNOS structure [37,64]. The crystal structure showing the 
binding mode of the natural substrate, arginine, with rat 
nNOS was elucidated in 2003 (PDB code 1OM4, unpub-
lished article) along with the binding modes of arginine like 
inhibitors in rat nNOS. (PDB code 1K2R, unpublished arti-
cle). This represented a significant advance in the field of 
NOS inhibition as, for the first time detailed information 
describing the rat nNOS ligand binding pocket was available. 
An image of this arginine binding site, with L-NNA bound, 
is provided in Fig. (13). 
 
 
Fig. (12). Bovine eNOS with L-NNA (compound 7) bound with 
heme and the ligand. (PDB:8NSE) [61]. 
 
 
Fig. (13). Rat nNOS arginine binding site with the L-NNA (com-
pound 7) bound (PDB: 1K2R). Waters involved in solvent mediated 
interactions between Asp597 and L-NNA have been included. BH4 
has been omitted for clarity. 
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Glu592 (Glu363 in bovine eNOS) was observed to form 
several HB interactions with the nitro guanidino group of the 
L-NNA inhibitor. Asp597 was also involved in binding via 
water mediated electrostatic interactions with the primary α 
amino group of the inhibitor. The C terminal carboxyl group 
of L-NNA undergoes HB with Gln478, Arg481 and Ser477 
while the side chain amino group interacts via a water mole-
cule with the heme propionate [65].  
The availability of both bovine eNOS and rat nNOS crys-
tal structures allowed for detailed selectivity studies of the L-
NNA based inhibitors. Flinspach et al. [65] observed Ki val-
ues of 0.13 µM, 0.12 µM and 0.07 µM for rat nNOS for 
compounds 8, 9 and 10 respectively (Fig. 14). These same 
compounds had Ki values of 200 µM, 300 µM and 130 µM 
respectively for bovine eNOS.  
In the rat nNOS binding site, the inhibitors bound in a 
manner similar to that observed for L-NNA. The gua-
nidine mimic made a bifurcated HB with Glu592. The 
nitro group of the inhibitors made an additional HB with 
the protein backbone, strengthening the interaction of the 
inhibitors with the binding site. In bovine eNOS the in-
hibitors make the same interactions with the equivalent 
glutamic acid, Glu363. In eNOS, either the guanidine to 
glutamate bond, or the nitro to backbone HB is stretched 
slightly (~3.2 Å) which partly explains the selectivity of 
the compounds. The most important difference between 
eNOS and nNOS however was thought to be the replace-
ment of Asp597 in nNOS with Asn368 in eNOS. It was 
hypothesised that the presence of the negatively charged 
residue in nNOS encouraged the inhibitors to adopt a 
curled configuration. This allowed the α amino group on 
the inhibitors to be stabilised by both Asp597 and Glu592 
in nNOS. In eNOS, this dual stabilisation was not possible 
as the aspartic acid was replaced by an asparagine [65]. 
The extended binding conformation of compound 10 in 
eNOS and its curled binding conformation in nNOS are 
shown in Fig. (15). 
Building on these observations Ji et al. made use of com-
pound 10 and molecular interaction field (MIF) analysis to 
examine the binding sites of rat nNOS, bovine eNOS and 
human iNOS [66]. Probes covering hydrophobic, steric and 
HBA/HBD interactions were used to calculate MIFs in the 
 
Fig. (14). Compounds 8, 9 and 10 used by Flinspach et al. to examine the basis of selectivity between nNOS and eNOS [65]. 
 
     
Fig. (15). Bovine eNOS with compound 10 bound in extended conformation (PDB: 1P6N) vs rat nNOS with compound 10 bound in curled 
conformation (PDB:1P6J). Notice the proximity of the primary amine of the inhibitor to E592 in rat nNOS (2.8 Å), while the equivalent pri-
mary amine is further removed from E363 in bovine eNOS (5 Å) [65].  
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active sites of the three NOS isoforms. The most important 
determinants for rat nNOS selectivity were identified as hy-
drophobic and charge-charge interactions [66]. 
Binding modes were explored by flexibly docking 25 
known NOS inhibitors (including the dipeptides shown in 
Fig. 14) into the binding site of the three NOS isoforms us-
ing AutoDock3 [67]. The combined GRID [68]/CPCA (con-
sensus principal component analysis) and docking approach 
identified regions important for selectivity and yielded in-
sights into important protein-ligand interactions [66]. Four 
pockets were identified, termed the S, M, C1 and C2 pockets 
(see Fig. 16). In rat nNOS the S pocket is found above the 
heme ring and is comprised of residues Phe584, Val567 and 
Pro565. The M pocket is located between the substrate cata-
lytic site and the substrate access channel. This pocket in-
cludes the residues Asp597, Ser477, Ser568, Gln478, 
Arg481, Asn569 and Arg603. The C1 and C2 pockets are a 
little removed from the substrate binding cavity and consti-
tute the substrate access channel. The C1 pocket contains 
Met336, L337, Glu307, Asn601 and Ser602 while the C2 
pocket contains Pro708, Asp709, Pro710 and Gln500. 
The S pocket (with the exception of the Asn370Ser dif-
ference in iNOS) is identical in the three NOS isoforms used 
in this study, (rat nNOS, bovine eNOS and human iNOS). 
As such, it is difficult to explain the selectivity exhibited by 
some L-arginine analogues when only considering binding in 
the S pocket. 
From the analysis of several probes, e.g. DRY (hydro-
phobic probe) and N1+ (charged probe), a ligand with a hy-
drophobic functional group interacting at the M pocket was 
proposed to improve selectivity towards human iNOS. The 
M pocket is defined by residues Ser477 and Ser568 in rat 
nNOS or Ala262 and Ala353 in human iNOS, which are 
postulated as being responsible for selectivity between the 
two isoforms. Alternatively, introduction of a positively 
charged functional group would be unfavourable for eNOS 
binding in the M pocket. The nNOS M pocket is a more 
negative environment than the eNOS M pocket, with rat 
nNOS residue Asp597 being replaced by Asn368 in the bo-
vine eNOS M pocket. This highlighted the significance of 
the M pocket in the design of isoform selective ligands.  
The C1 pocket differs among the NOS isoforms (rat 
nNOS, bovine eNOS and human iNOS) at five residues. 
Two selective regions were found, the first at residues 
Met336 and Leu337 of rat nNOS and another at residues 
Glu307, Asn601 and Ser602 of rat nNOS. A histidine resi-
due, His342 in human nNOS, (equivalent to Met336 in rat 
nNOS) could potentially be used to guide selective ligand 
design.  
There are four residues in the C2 pocket that differ across 
the NOS isoforms (rat nNOS, bovine eNOS and human 
iNOS). The most important residues determined for selectiv-
ity are at the rat nNOS Asp709/human iNOS Glu494 posi-
tions. The authors postulated that inhibitors with a positively 
charged functional group positioned near the Asp709 of rat 
nNOS should be selective towards nNOS [66]. 
2.4.2. 2-Aminopyridine containing inhibitors 
The 2-aminopyridine class of NOS inhibitors target the 
arginine binding pocket and as their name suggests contain 
both a pyridine and amine functionality. It had been previ-
ously observed, prior to the elucidation of the rat nNOS crys-
tal structure, that 2-aminopyridines (compound 11) [69] and 
quinazolines (compound 12) [70] were inhibitors of NOS 
(Fig. 17). 
The recent in silico driven era of NOS inhibitor devel-
opment attempted to build on these known inhibitor scaf-
folds with Garcin et al. employing an anchored plasticity 
approach [71]. The known binding mode of the 2-
aminopyridine and the quinazoline was conserved in the ar-
 
Fig. (16). Binding pockets of the rat nNOS arginine active site as defined by Ji et al. [66] with L-NNA bound (compound 7), (PDB:1K2R). 
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ginine binding site, and various substituents were attached to 
the inhibitor scaffolds in an attempt to improve inhibitor 
efficacy and selectivity. It was envisaged that the known 
scaffold would maintain inhibitor binding, while the various 
substituents would allow the inhibitor to interact with other 
parts of the arginine binding site. Of particular interest were 
those areas of the binding site that contained residues which 
were not conserved across the three isoforms and which 
could be exploited so as to improve inhibitor selectivity. Us-
ing this method, Garcin et al. developed a novel series of 
NOS inhibitors [71] with one of the most efficacious com-
pounds being the human iNOS inhibitor shown in Fig. (18) 
(Compound 13). 
 
NH2N
N
H
N
NH2F
F
O
Compound 11 Compound 12  
Fig. (17). 2-Aminopyridine (compound 11) and quinazoline (com-
pound 12) NOS inhibitors [69,70].  
 
 
Fig. (18). iNOS selective inhibitor, compound 13, derived from 
anchored plasticity studies. This compound has an iNOS IC50 of 
0.074 µM with a 100 fold eNOS selectivity and 6 fold nNOS selec-
tivity [71]. 
 
Protein crystallization studies of compound 13 (and other 
similar compounds) with human iNOS revealed that binding 
did indeed occur at the arginine binding site. Similar to the 
guanidinium group of arginine, the cis amidine moiety gen-
erated a HB to the glutamic acid located at the bottom of the 
binding site. The inhibitor also π stacked with the heme 
group. The 4-cyanobenzoylpiperidinyl tail of the inhibitor 
was located above the heme moiety where it packed with 
Gln257, Arg260, Pro344, Ala345 and Arg382. The rigid tail 
of the inhibitor forced a rotation of the Gln257 residue of 
iNOS. This is referred to by the authors as the Gln open con-
formation of iNOS. The rotation of Gln257 generates a con-
formational change at Arg260. This shift is stabilized by a 
HB interaction between Arg260 and Thr277. The opening of 
this pocket upon inhibitor binding is not observed for eNOS 
and nNOS as Thr277 of iNOS is replaced by the sterically 
bulkier Asn269/498. The authors suggested that this pocket 
opening forms the basis for the iNOS selectivity observed 
with these compounds. An image of the Gln open conforma-
tion of murine iNOS with compound 13 bound is provided in 
Fig. (19). 
An alternative approach was adopted by Ji et al., [72] 
who described fragment hopping as a de novo inhibitor de-
sign approach that focused on the derivation of the “minimal 
pharmacophore element” for each NOS isoform. Sites for 
both ligand binding and NOS enzyme selectivity can be con-
sidered for deriving this minimal pharmacophore element. 
Building on a previous study [66] the active site of NOS was 
again divided into the four pockets S, M, C1 and C2. The S 
pocket is found above the heme ring while the M pocket is 
located between the substrate catalytic site and the substrate 
access channel. Again, the C1 and C2 pockets are slightly 
removed from the substrate binding cavity and constitute the 
substrate access channel (Fig. 16). 
 
 
Fig. (19). Gln open conformation of iNOS with compound 13 
bound. (PDB:3EAI) [68]. 
 
For selective nNOS inhibitor design an aminidino group 
was positioned close to Glu592; a nitrogen atom was near to 
the selective region defined by Asp597 of rat nNOS; three 
nitrogen atoms were placed close to the heme propionate to 
form a charge-charge interaction and HBs; in the S pocket, 
hydrophobic and/or steric interactions played important roles 
in ligand binding [72].  
Based on each minimal pharmacophoric element, frag-
ments with different chemotypes were generated using a 
fragment and a bioisostere library. Fragments were docked 
into the active site of nNOS, where the corresponding phar-
macophore features were located, and subsequently linked. 
To circumvent issues arising from synthetic feasibility, 
common chemical bonds in drugs or drug candidates were 
considered preferentially [72]. A 2-amino pyridine com-
pound, compound 14, which exhibited nano-molar rat nNOS 
inhibitory potency and 1,000-fold rat nNOS selectivity over 
bovine eNOS, was identified (Fig. 20). 
 
NH2N NH
NH2
NH2
-+  
Fig. (20). Compound 14 developed by fragment screening [72]. 
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The 2-aminopyridine 14, (Fig. 20), is quite polar and may 
not cross the blood brain barrier (BBB). As a result, Ji et al. 
built on this work by designing nNOS inhibitors with in-
creased lipophilicity and optimized in vivo potency and se-
lectivity [73]. In the GRID [68] analysis of rat nNOS, two 
hydrophobic areas were identified, one surrounded by 
Met336, Leu337, Tyr706 and Trp306 in the C1 pocket and 
another lined by Pro565, Ala566, Val567 and Phe584 in the 
S pocket (Fig. 16). In addition, two significant areas for 
steric probes were identified, one in the S and one in the M 
pocket. These regions were used to generate minimal phar-
macophoric elements. Several compounds were generated 
with the LUDI program [74] which employed lipophilic 
fragments for lead optimization. This fragment-based 
method allowed the development of compounds with im-
proved pharmaceutical properties and enhanced potency and 
selectivity. One such compound is the 2-aminopyridine 15, 
which has a Ki of 0.014 µM molar for rat nNOS inhibition 
and 2,000 fold selectivity over bovine eNOS and 290 fold 
over murine iNOS. The 2-aminopyridine 15 was initially 
tested as mixture of diastereomers [73] (Fig. 21). The four 
stereoisomers were subsequently resolved [75] (Fig. 21). 
The binding modes of the enantiomers 15 S,S and 15 R,R 
with rat nNOS were reported in detail [75]. Compound 15 
S,S interacts via HBs between the conserved Glu592 at the 
bottom of the arginine pocket and the 2-aminopyridine on 
the inhibitor. Water mediated HBs formed with Asp597 and 
the 2-aminopyridine formed a π-π interaction with the heme. 
The flourophenyl arm was located in the hydrophobic pocket 
formed by Met336 and Leu337 (Fig. 15). This is referred to 
as the “normal” binding mode of nNOS inhibitors by the 
authors, with the 2-aminopyiridine interacting with Glu592. 
Interestingly the R configured inhibitor (15 R,R), adopted a 
different and novel binding mode with rat nNOS. This 
“flipped” binding mode saw the flourophenyl group orien-
tated above the heme moiety. This then formed a π stacking 
interaction with the porphyrin ring. The 2-aminopyridine 
motif extended away from the heme moiety and induced a 
conformational shift in Tyr706, causing this residue to move 
away from the aminopyridine. The aminopyridine then 
formed a bifurcated salt bridge with the heme propionate A, 
as well as a π stacking interaction with the Tyr706. HB inter-
actions are also observed between the pyrrolidine ring and 
the heme propionate B.  
The R,R stereoisomer possesses remarkable selectivity, 
with the rat nNOS Ki value being 3,800 and 700 times lower 
than that for bovine eNOS and murine iNOS respectively. In 
rat nNOS, the 4 methyl group is accommodated by a hydro-
phobic pocket comprised of Met336, Leu337 and Trp306. 
This pocket is not available in iNOS, hence the selectivity 
over this isoform. The eNOS selectivity is more difficult to 
explain as the crystal structure studies suggest that the bind-
ing mode for 15 R,R in eNOS and nNOS is the same [75]. 
Some selectivity differences between the two isoforms can 
be explained by residue differences between the eNOS and 
nNOS arginine binding pockets, with Asp597 in nNOS be-
coming Asn in eNOS and Met336 in nNOS becoming Val in 
eNOS. However mutation studies indicated that these residue 
differences were not the only contributory factors for selec-
tivity [75]. Mutation studies also indicated that the flexible 
Tyr706 contributes significantly to binding in nNOS, while 
contributing very little to binding in eNOS. Therefore, tar-
geting the Tyr706 site with these new flipped binding mode 
compounds offers the potential of highly selective and effi-
cacious nNOS inhibitors.  
Compounds such as 15 S,S and 15 R,R have great poten-
tial as nNOS inhibitors. However, their development was 
hampered by their somewhat poor “drug-like” properties as 
both 15 S,S and 15 R,R have a large number of rotatable 
bonds and contain several ionisable groups. Attempts have 
been made to improve the drug-like features of these com-
pounds and to make them more pharmacokinetically and 
pharmacodynamically favourable [76]. These studies re-
sulted in further modifications to the 2-aminopyridines and 
generated compounds such as 16 and 17, shown in Fig. (22).  
Compound 16 has a Ki of 7 nM for rat nNOS, 2,667 fold 
selectivity over bovine eNOS and 806 fold selectivity over 
murine iNOS [76]. Compound 16 was shown to adopt the 
flipped mode of binding (Fig. 23), as previously described, 
where the 2-aminopyridine interacts with Tyr706 to improve 
the binding affinity for nNOS [77]. As before, inverting both 
stereocenters (compound 17) resulted in a switching of bind-
ing mode to the “normal” mode (Fig. 24), indicating the cru-
cial role stereochemical considerations must play in nNOS 
inhibitor design (Figs. 23 and 24). Compound 17 has a Ki of 
220 nM for rat nNOS, 270 fold selectivity over bovine eNOS 
and 60 fold selectivity over murine iNOS [78]. 
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Fig. (21). Unresolved aminopyridine 15 [73] and the subsequently resolved stereoisomers [75]. The 3S,4S (compound 15 S,S) and 3R,4R 
(compound 15 R,R) stereoisomers had Ki values of 52.2 nM and 5.3 nM respectively for rat nNOS. 
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Other modifications have been made to these scaffolds, 
such as introducing a cyclopropyl ring or a methyl group 
adjacent to the fluoro substituted aromatic ring (compounds 
18 and 19) [79]. Difluoroination at this position has also 
been examined, compound 20. This has IC50 values of 0.170 
µM, 0.046 µM and 0.080 µM for rat nNOS respectively 
[77,79]. All compounds were tested as racemates (Fig. 25).  
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Fig. (22). Modified 2-aminopyridine, compound 16 and its di-
astereomer, compound 17 [76]. 
 
 
Fig. (23). Compound 16, in the flipped binding mode (PDB:3NLM) 
[77]. Note how Y706 is orientated to interact with the 2 aminopyri-
dine ring. 
 
Huang et al. [76] also developed a series of pyrrolidine-
based 2-aminopyridines that exhibited a “normal” and 
“flipped” binding mode in rat nNOS. Both the binding mode, 
and the mechanism by which the ligand leaves the binding 
pocket of nNOS, was explored using steered molecular dy-
namics (SMD). In the SMD approach, forces are applied to a 
ligand to manipulate its structure by pulling it along desired 
degrees of freedom. Regions A, B and C were defined in the 
binding site (Fig. 26) and the type of moiety that could bind 
in each region was postulated. Region A could bind an aro-
matic ring facilitating stacking with the heme and interac-
tions with Glu592. Region B could be the anchoring compo-
nent that would interact with heme propionate A or Asp597. 
Finally, region C could be an aminopyridine fragment to 
enhance affinity through the bifurcated HBs with heme 
propionate D and the π-stacking interaction with Tyr706. 
 
Fig. (24). Compound 17, in the normal binding mode. 
(PDB:3NLK). Note how the Y706 does not position itself to inter-
act with the flourophenyl ring [77].  
 
 
Fig (25). Cyclopropyl (compound 18) [79], methyl (compound 19) 
[79] and difluoro (compound 20) [77] substituted scaffolds. 
 
A series of compounds containing two pyridine rings 
were synthesised to validate the simulation predictions [76]. 
Compound 21 (Fig. 27) exhibited a Ki of 0.03 µM for rat 
nNOS with a rat nNOS over bovine eNOS selectivity of 
1,117 and a rat nNOS over murine iNOS selectivity of 619. 
Compound 21 also demonstrated improved membrane per-
meability, at 3 µM, for the aminopyridine based nNOS in-
hibitors. The metabolic stability of 21 was also examined. 
The in vitro metabolic rate was 0.02 (nmol/min/mg protein) 
with 85% of compound 21 remaining after 60 min in the 
presence of NADPH [76]. 
Despite the success of 21 and other similar compounds, 
the chiral pyrrolidine containing aminopyridine scaffold is 
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not particularly suitable for further development due to syn-
thesis and purification difficulties. In addition, the scaffold 
was not very drug like, having multiple ionisable groups and 
poor BBB characteristics. As previously discussed, reports 
on the 2-aminopyridine motif indicated that it was capable of 
binding to NOS in two orientations, the “normal” and 
“flipped” depending on the stereochemistry of the pyr-
rolidine ring substituents. Xue et al. reasoned that by com-
bining two identical 2-aminopyridine motifs via a central 
linker both binding modes could be achieved with a single 
compound [80]. The most potent compound to result from 
this structure activity relationship (SAR) study was com-
pound 22 (Fig. 28) which had a Ki of 25 nM for rat nNOS, 
and a 107 and 58 fold selectivity over bovine eNOS and 
murine iNOS respectively [80].  
 
 
Fig. (26). Huang's regions A, B and C of the rat nNOS arginine 
binding pocket [76] (PDB: 1K2R, unpublished). 
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Fig. (27). Huang et al.’s aminopyridine, compound 21 [76]. 
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Fig. (28). Xue et al.’s compound 22 [80]. 
 
One of the most interesting features of compound 22 was 
its binding mode as determined by crystallization of com-
pound 22 with rat nNOS (Fig 29). [81] It was observed, as 
expected, that compound 22 used one of the 2-aminopyridine 
moieties to form a network of HBs with Glu592 and Trp587. 
The second 2-aminopyridine moiety formed HB interactions 
with one of the heme propionates as well as a π-π interaction 
with Tyr706. Unexpectedly, a second molecule of compound 
22 binds to the BH4 binding site by using the central pyridine 
nitrogen to interact with the zinc atom present in the BH4 
site. This results in the displacement of the BH4 and a rear-
rangement of several residues, in particular Arg596, which 
moves to interact with Glu592 and Asp600 of the substrate 
binding site. This movement opens a second zinc binding 
site in nNOS. The binding of a second zinc atom results in a 
tightening of the dimer interface in nNOS. This opening of a 
second zinc binding site is not observed in eNOS, potentially 
due to the tighter dimer interface of this enzyme. This may 
explain the selectivity of compound 22 for nNOS over 
eNOS. 
 
Fig. (29). Dual diaminopyridine compound 22 binding to both the 
arginine and the BH4 binding sites. (PDB: 3N5W) [81]. 
 
Several pharmaceutical companies have also explored the 
use of 2-aminopyridines as nNOS inhibitors. In a 2004 
study, Pfizer published a series of eight compounds which 
inhibited human nNOS, the most efficacious of which was 
compound 23, with a IC50 of 54 nM [82] (Fig. 30). Studies 
exploring the binding mode of this family of compounds 
were not published. Animal studies employing the Pfizer 
compounds were mentioned in their 2004 paper but did not 
appear in the literature to the best of our knowledge.  
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Fig. (30). Pfizer’s 2-aminopyridine, compound 23 [82]. 
 
2.4.2.1. MD Studies of Binding Modes of L-NNA and 2-
Aminopyridines 
Compound 13, Fig. (18) and compound 15 R,R, Fig. 
(21) were previously synthesised and evaluated by Garcin 
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et al. [71] and Ji et al. [75] respectively. Recently, Oliveira 
et al. studied the precise binding mode of L-NNA and the 
protonated forms of 13 and 15 R,R (Fig. (31) using compu-
tational methods. Oliveira et al. first validated their com-
pound docking protocol by re-docking the crystal structure 
ligand into the binding pocket. Following docking of the 
protonated versions of compound 13 and 15 R,R they im-
plemented 8 ns MD simulations for murine iNOS, bovine 
eNOS and rat nNOS monomers [83]. MD simulations are 
frequently used to monitor interactions and conformational 
changes over a time period in an effort to incorporate re-
ceptor/ligand flexibility and induced fit into studies. This 
publication offered an excellent insight into the predicted 
binding modes of the two main nNOS inhibitor classes, 
substituted arginines and 2-aminopyrines, and so will be 
discussed in detail. 
 
Fig. (31). Protonated versions of compound 13 [71] and compound 
15 R,R [75] computationally studied by Oliveira et al. [83]. The 
medicinal chemistry papers of Garcin et al. [71] and Ji et al. [75] 
reported the original synthesis and evaluation of 13 and 15 R,R 
from which the protonated species shown here are derived. 
 
L-NNA is moderately selective for nNOS over eNOS and 
iNOS with IC50 values of 0.29 µM, 0.35 µM and 3.1 µM 
respectively. The MD simulations revealed that this selectiv-
ity was due to two binding modes which L-NNA could 
adopt. In nNOS, the inhibitors bind in an “extended” con-
formation (Fig. 13). This is facilitated by an interaction 
which forms between the L-NNA carbonyl group and 
Arg481. This interaction cannot be achieved in iNOS due to 
a change of Asn498 in nNOS to Thr277 in iNOS. In nNOS, 
Asn498 induces a rotation in Arg481, allowing Arg481 to 
interact with the carbonyl group of L-NNA. In iNOS, Thr277 
does not induce rotation in the corresponding arginine 
(Arg260). L-NNA therefore adopts a “curled” conformation 
in iNOS, pushing the carbonyl group close to Asp376. This 
results in electronic repulsion between the inhibitor and the 
binding site. This explains the higher binding affinity of L-
NNA for nNOS over iNOS. 
L-NNA uses this “curled” mode of binding in eNOS for 
similar reasons. The inhibitor is slightly more potent against 
eNOS than iNOS due to the change of Asp376 in iNOS to 
Asn368 in eNOS. This mutation reduces the electronic repul-
sion between the binding site and L-NNA in eNOS, which 
results in tighter binding. The affinity of the protonated 
aminopyridine 13 for iNOS could be explained by the forma-
tion of an iNOS specific sub-pocket upon binding. The abil-
ity of Glu363 to adopt different conformations has already 
been observed in X-ray crystal structures. The lack of affin-
ity for eNOS was associated with a conformational change in 
Glu363 [84,85].  
In all three isoforms the protonated version of 13 adopts 
the “normal” binding mode, with the 2-aminopyridine moi-
ety positioned near the heam moiety, allowing it to form a 
bidentate HB with a Glu residue (Glu592 in rat nNOS, 
Glu363 in bovine eNOS and Glu371 murine iNOS). The 
binding of the 2-aminopyridine moves the pyridine ring par-
allel with the heme in iNOS and nNOS, thus facilitating 
formation of π- π interactions between the two aromatic 
rings. The bulkier residues of the eNOS binding pocket do 
not allow the aminopyridine and the heme rings to orientate 
themselves parallel to each other. Therefore the π- π interac-
tion does not form in eNOS. Oliveria et al. suggest that this 
explains the lower affinity of protonated compound 13 for 
eNOS over iNOS and nNOS. In iNOS and nNOS the π- π 
interaction pushes the cyanobenzyl above the heme moiety 
allowing it to interact with Gln257 in iNOS and Gln478 of 
nNOS. In iNOS, this induces the Gln “open” conformation 
as previously described by Garcin [71]. The Gln “open” con-
formation is not observed for nNOS, thus explaining why the 
protonated version of compound 13 favours iNOS over 
nNOS.  
The MD simulations suggested why the protonated form 
of compound 15 R,R favours nNOS binding over eNOS or 
iNOS. Binding of the protonated compound 15 R,R to eNOS 
results in rotation of Glu363 with an associated energy pen-
alty of 1-2 kcal mol -1 [83]. Also, the nNOS arginine binding 
pocket was calculated to have a volume of 2203 +/- 8.3 Å3, 
while eNOS is slightly larger at 2489.0 +/- 7.7 Å3 [83]. The 
larger pocket of eNOS is suggested to result in weaker Van 
der Waals interactions between the protonated form of 15 
and eNOS. In iNOS, it was observed that the fluorophenyl 
group is not parallel to the heme moiety while in nNOS and 
eNOS the two rings are parallel, thus enabling π- π interac-
tions. This may explain why the protonated compound 15 
R,R is not as potent against iNOS as it is for eNOS and 
nNOS.  
2.4.3. Thiophene Scaffold Inhibitors 
AstraZeneca have published several thiophene contain-
ing compounds that act as NOS inhibitors. These com-
pounds retained the same “normal” binding interactions 
within the rat nNOS arginine pocket where the amidine 
interacts with the conserved Glu592 and the secondary 
amine forms an interaction with the heme propionate [86]. 
The chlorophenyl ring is accommodated by the hydropho-
bic pocket consisting of Tyr706, Leu337 and Met336 and 
the interaction is further stabilised by pi stacking with the 
Tyr706 aromatic ring. Compound 24 has IC50 values of 
0.035 µM, 3.5 µM and 5 µM against nNOS, eNOS and 
iNOS respectively (Fig. 32). 
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Fig. (32). AstraZeneca’s thiophene based inhibitor, compound 24 
[86]. 
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Sanofi-Aventis have also examined thiophene scaffolds 
as potentially selective nNOS inhibitors. In a 2011 publica-
tion Liang et al. reported a series of compounds with IC50 
values ranging from 17 nM to 706 nM against nNOS [87]. 
The most potent of these was compound 25 (Fig. 33). This 
displayed a 1,664 fold selectivity for rat nNOS over bovine 
eNOS. 
 
 
Fig. (33). Compound 25, with IC50 of 17nM for rat nNOS [87]. 
 
Neuraxon employed a thiophene/guanidinium combina-
tion in their SAR studies [88]. Here they developed a series 
of compounds containing a thiophene, a guanidinium group 
and a hydrocarbon chain linked to an amine functionality. 
Their most successful inhibitor was compound 26 (Fig. 34) 
with an IC50 of 97 nM for human nNOS [88]. This com-
pound displayed 33 fold and greater than 100 fold, selectiv-
ity over human eNOS and human iNOS respectively. 
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Fig. (34). Neuraxon’s nNOS inhibitor compound 26 and the secon-
dary amine version developed to ameliorate hERG channel interac-
tions, compound 27 [88]. 
 
Replacement of the methyl group on the tertiary nitrogen 
with a hydrogen (compound 27, Fig. 34) was observed to 
greatly reduce hERG channel interaction, with the IC50 in-
creasing to 139 nM. This secondary amine containing com-
pound was observed to be orally bioavailable and effective in 
the Chung pain model of rats [89]. The binding mode of this 
compound has not been elucidated to the best of our knowl-
edge.  
2.4.4. FeS Coordinating Inhibitors 
Imidazole containing compounds have also been ob-
served to bind to the arginine binding site, but in a slightly 
different manner. This class of compound coordinate to the 
heme Fe at the centre of the active site via an imidazole ni-
trogen. Imidazole itself is a weak inhibitor of nNOS, with an 
IC50 of 290.6 µM [90]. Various substituents have been added 
to imidazole in an attempt to improve its efficacy as a nNOS 
inhibitor. These substituents include phenyl rings (compound 
28) [91] and various amino acids (compound 29) [92, 93] 
(Fig. 35). 
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Fig. (35). Phenyl [91] and amino acid [93] substituted imidazoles, 
compounds 28 and 29, with nNOS IC50 values of 25 µM and 19 µM 
respectively. 
 
Other heme co-ordinating inhibitors have been designed 
using in silico methods. L-thiocitrulline, an arginine analogue 
with the terminal guanidine-nitrogen replaced by sulphur, 
was active against rat nNOS and reported to coordinate to 
the heme iron [94]. Litzinger et al. [95] proposed combining 
the key features of L-thiocitrulline with amino acid substi-
tuted imidazoles. This new class of inhibitor was docked 
with rat nNOS using the FlexX [96] program and compound 
30 (Fig. 36) was predicted to be positioned with the sulphur 
close to the heme and coordinated to the Fe.  
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Fig. (36). Iron co-ordination nNOS inhibitors, compounds 30 and 
31 [95,97]. 
 
Compound 30 exhibited good potency (Ki of 0.37 uM) 
and moderate selectivity for rat nNOS (185 fold for rat 
nNOS over bovine eNOS and 3.12 fold for rat nNOS over 
murine iNOS). In contrast to the docking predictions, ex-
perimental difference absorption spectra indicated a type I 
spectrum when compound 30 was added to imidazole satu-
rated nNOS. Absorption spectra categorised as a type I spec-
tra, with a peak at ~400 nm and a trough at 437 nm, are in-
dicative of a pentacoordinate high spin heme iron. While a 
type II spectrum, such as that for a known Fe coordinating 
ligand (e.g. imidazole), displays a peak at 432 nm and a 
trough at 393 nm. The observed type I spectrum indicates 
that the sulphur containing chain does not interact with the 
heme iron as predicted. Subsequently, the group postulated 
that the sulphur containing chain binds preferentially in the 
hydrophobic pocket at the top of the active site [95]. 
The same group then analyzed potential ligand-enzyme 
interactions in the hydrophobic pocket defined by Pro565, 
Val567, and Phe584 of rat nNOS [97]. This pocket can also 
accommodate small alkyl groups, with inhibitors anchored in 
the active site through a HB with Glu592. Based on this 
analysis compound 31 (Fig. 36) was designed, which was 
confirmed to be a type II ligand by UV-vis spectrophotome-
try and crystallography (type II inhibitors convert the high-
spin heme of BH4-nNOS to a low spin state, resulting in a 
red shift in the Soret absorption and a type II visible differ-
ence spectrum) [97]. The crystal structure of compound 31 
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with rat nNOS revealed that the two methylene groups, sepa-
rating the amidine from the sulphur, afforded the flexibility 
needed to place the sulphur directly over the heme iron. The 
terminal ethyl group fits into the hydrophobic pocket formed 
by Pro565, Val567 and Phe584 and the Fe-S distance is 2.5-
2.6 Å (Fig. 37). 
 
 
Fig. (37). Compound 31 co-crystallized with rat nNOS (PDB:3JT4) 
[97]. 
 
2.4.5. Recent Advances in nNOS Inhibitor Design & Opti-
mization 
Virtual screening is often used as an alternative to high 
throughput screening, in an effort to reduce both cost and 
time [98]. The approach can be validated initially through 
the use of theoretical test/validation sets and subsequently 
through experimental evaluation of the identified com-
pounds. Xu et al. [99] performed a tiered virtual screening 
study incorporating development of a seven feature NOS 
pharmacophore, a Comparative Molecular Field Analysis 
(CoMFA) comparison and docking studies using a rat nNOS 
crystal structure. The pharmacophore model incorporated 
three hydrophobes, one donor atom, one acceptor atom and 
two positive nitrogens and was in general agreement with the 
CoMFA model. Here, tiered virtual screening of the Specs 
database of 197,000 compounds was pursued by filtering 
first by the pharmacophore query, by Lipiniski rules and by 
Qfit [100]. Subsequently, the filtered compounds were fur-
ther examined by flexible docking. From this 10 compounds 
were identified as potential selective human nNOS inhibitors 
but remain to be experimentally validated. The top three 
ranking compounds from this screen are shown in Table 2.  
Recently, Kumar et al. [101] developed a QSAR model 
of a series of 3,4-dihydro-1-isoquinolinamines and thieno-
pyridines that were reported as potent, highly selective in-
hibitors of nNOS and eNOS. The QSAR models for nNOS 
and eNOS inhibition potency were indicated to involve a 
hydrophobic (ClogP) and a steric (calculated molar refractiv-
ity, CMR) interaction respectively. Through docking studies 
the possible orientations of the compounds with the enzymes 
were modelled. Compound 32 (Fig. 38) was predicted to 
form a HB through the 6-NH2 group with Pro450 and 3 HBs 
between the 10-NH2 group and Val449, Pro450 and Pro451 
of eNOS. Alternatively, compound 33 was predicted to form 
HBs through its 6-NH2 group with Ala446, Trp447 and 
Val449 of nNOS.  
 
Table 2. Xu et al.’s predicted nNOS inhibitors [99]. 
Structure 
Dock 
Score 
QFIT 
 
8.29 65.74 
 
8.20 65.74 
 
8.01 65.82 
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Fig. (38). Kumar et al.’s compounds 32 and 33 utilised in a QSAR 
study [101]. 
 
3. PHARMACOKINETICS OF nNOS INHIBITORS 
The BBB blocks certain drugs, chemical compounds and 
viruses from gaining access to the CNS from the blood-
stream. In general, CNS drugs have a smaller range of mo-
lecular weights, and smaller number of hydrogen bond donor 
and acceptors than general therapeutics [102]. A large num-
ber of charges and hydrogen bond donors can impede the 
ability of molecules to cross the BBB and thereby limit the 
effectiveness of potential neurological therapeutics.  
In the nNOS arena, a number of medicinal chemistry ap-
proaches have been pursued to improve PK properties 
[103,104]. For example, a prodrug approach was employed 
that involved replacing one of the secondary amino groups 
on a pteridine NOS inhibitor (which binds in the BH4 
pocket) with an amide or carbamate [36], (scaffolds shown 
in Fig. 6). This was reported to improve BBB penetration by 
lowering the charge, removing two HBDs and raising the 
predicted logD [36]. Additionally, amino groups which ex-
hibited a high pKa have been replaced by ethers and amides 
in 2-aminopyridines [105], (Fig. 39). The resultant ether ana-
logue maintained a similar potency and selectivity but with 
an increased ability to penetrate the BBB, as evidenced by an 
increased brain to blood concentration ratio [105]. Acety-
lated and carbamoylated prodrug analogues of compound 21, 
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reported by Silverman and co-workers, have increased lipo-
philicity and lowered charge, but surprisingly, did not cause 
an increase in BBB penetration (Fig. 40) [106]. Over a 20 
minute experiment there was little difference between the 
overall brain concentrations of the tested prodrug analogues 
of 21. 
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Fig. (39). Compound 15 S,S [72] with a secondary amine, and com-
pound 16 [73] with an ester linkage which were used to study how 
substitution patterns affected passage of nNOS inhibitors across the 
BBB [105]. 
 
 
Fig. (40). Compound 21 and three prodrug analogues of same. Sil-
verman et al. 2009 [106]. 
 
The addition of an intramolecular HB is another known 
strategy used in PK and BBB optimisation of novel inhibi-
tors for a variety of enzymes [107-111]. In an effort to ex-
ploit this strategy, nNOS aminopyridine inhibitors were de-
signed with intramolecular hydrogen bonding motifs in the 
hope of improving cell membrane permeability [112]. In this 
study, inhibitors such as compound 34 were hypothesised to 
form a “closed” conformation through intramolecular HB 
formation, which would decrease the overall polarity of the 
compound and potentially improve BBB permeability. Once 
the inhibitor bound to nNOS it might form alternative inter-
molecular interactions and stabilize an “open” conformation 
[112] (Fig 42). Some synthesised compounds capable of 
intramolecular HB formation exhibited an improved relative 
permeability index (RPI), indicative of an increased cell 
membrane penetration ability e.g. a RPI of 3.1 was observed 
for compound 34 (Fig. 41). However, it appears that incorpo-
ration of an intra-molecular HB was not sufficient to enhance 
cell membrane permeability for other compounds with lipo-
philicity playing a larger role [112]. 
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Fig. (41). Labby et al.’s aminopyridine based inhibitor, compound 
34. This can form intramolecular HB between the secondary amine 
hydrogen and the methyl ester oxygen. This interaction is lost on 
inhibitor binding to nNOS [112]. 
 
 
Fig. (42). Compound 34 bound to rat nNOS arginine site. The in-
tramolecular hydrogen bond interaction between the secondary 
amine hydrogen and the oxygen of the methyl ester is disrupted on 
inhibitor binding. This was referred to as “open” binding of the 
inhibitor (PDB: 3TYM) [112]. 
 
Xue et al. [77] introduced an electron withdrawing CF2 
moiety to aminopyridine inhibitors in an effort to reduce the 
basicity of their hit compound and improve its bioavailability 
(Fig. 43). Molecular Mechanics Poisson-Boltzmann/Surface 
Area (MM-PBSA) calculations, used to compute the free 
energy for various protonation states of the molecules, were 
performed and compared with the experimental free energy 
data. This confirmed the likelihood that the low pKa amino 
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group is partially protonated when bound to the nNOS active 
site. The experimental pharmacokinetic data illustrated that 
the addition of CF2 had a marked effect on in vivo stability 
and oral bioavailability. For example, compound 20 exhib-
ited an in vivo compound half-life (t½) for i.v. dosing at 1 
mg/kg in rats of 7.5 hr; a t½ for oral dosing of 3.7 hr and an 
oral bioavailability of 22.2 % whereas compound 16 had a t½ 
for i.v. dosing at 1 mg/kg in rats of 0.33 hr; a t½ for oral dos-
ing that was too low to measure and an oral bioavailability of 
essentially 0 %, (Fig. 43). 
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Fig. (43). Aminopyridine inhibitors 16 and 20, as presented by Xue 
et al. [77]. 
 
In recent years, Kumar et al. [113] examined a number of 
computational BBB filter models and concluded that there 
remains an urgent need to generate larger and more diverse 
datasets with accurate measurements of logBB values (the 
logarithm value of brain to plasma concentration ratio). Ad-
ditionally, other factors can influence BBB penetration e.g. 
plasma protein binding, active efflux from the CNS etc. 
However, Ji et al. [72] advocated early ADME/Tox consid-
erations in de novo nNOS compound design, as this would 
allow the functional groups that potentially effect metabolic 
stability and toxicophores to be taken into account during the 
generation of the focused fragment library and the linking of 
fragments. Such ADME/Tox considerations included oral 
bioavailability (rule of 5); blood brain distribution; and 
metabolic stability (Metasite, 
http://www.moldiscovery.com/software/metasite). The group 
of Ji et al. used a property based strategy to evaluate 
ADME/Tox effect of molecules [114]. A similar approach 
has been applied to other NOS enzymes. Recently, Karta-
sasmita et al., [115] examined Asiatic acid derivatives as 
iNOS inhibitors. Their docking study was coupled with a 
rudimentary ADME prediction using PreADMET 
(http://preadmet.bmdrc.org). Where experimental PK data 
was available, the prediction tool was in good agreement for 
human intestinal absorption (HIA). Such computational tools 
can be used to focus at an early stage, on those inhibitors 
which have appropriate properties for oral administration. 
CONCLUSION AND FUTURE PERSPECTIVES 
A focus of this review was on the recent use of computa-
tional techniques in the design and optimization of nNOS 
selective inhibitors and an analysis of the success of such 
approaches. A variety of compound classes have been de-
signed and utilized as nNOS inhibitors targeting a selection 
of sites, including the BH4, CaM, NADPH and the arginine 
binding sites. 
Efforts have been made to inhibit the binding of the cru-
cial co-factor BH4 so as to slow NOS activity. This between 
NOS isoforms. The concern remains that in the absence of 
BH4 there may be a build-up of potentially harmful free radi-
cal species. Work has been conducted on inhibiting NOS-
CaM interactions. Interfering with CaM itself could have 
potentially serious consequences in vivo owing to the wide 
range of processes which CaM regulates. Also, targeting 
protein-protein interaction sites is considered to be difficult 
as the surfaces are usually solvent exposed and do not favour 
strong binding interactions. For the NADPH binding site of 
NOS, a nucleotide moiety mimicking NADPH linked to a 
conjugated push-pull chromophore with non-linear absorp-
tion properties has been explored as both a trigger and a 
shutter. However, due to the vast array of enzymes which 
bind NADPH and the tendency of these sites to be well con-
served, it is likely that any imaging agent would suffer from 
a lack of specificity.  
The best explored classes are the L-arginine mimics, 
which unsurprisingly replicate the binding mode of the natu-
ral substrate, and the 2-aminopyridines, which have been 
observed to bind in either a flipped or non-flipped orientation 
depending on substitution patterns. Other classes, including 
imidazole and thiophene analogues, have also been exam-
ined. While efficacious and selective compounds have been 
identified, challenges remain surrounding the suitability of 
these compounds for further development due to their phar-
macokinetic properties. 
Further development in the area of nNOS inhibition will 
rely on development of an all human isoform assay system. 
Throughout the literature there is inconsistency in what iso-
form of nNOS is used for testing (rat, porcine, human etc). 
There is also inconsistency in the types of assay used to test 
inhibitory compounds. These can vary between Griess based 
assays, haemoglobin conversion assays, radiolabelled assays 
and whole cell assays. This is compounded by the use of 
various isoforms for selectivity testing and examination of 
binding modes (comparing inhibition of rat nNOS with bo-
vine eNOS for example). This issue should be somewhat 
addressed by the very recent publication of the first human 
nNOS crystal structure [116]. A move to a uniform method 
of testing (both NOS isoform and assay system) will allow 
robust comparison of results and development of more effi-
cacious and selective nNOS inhibitors.  
As evidenced in this review a substantial body of work 
has been conducted on nNOS inhibition using a variety of 
approaches. Continued work in this area has the potential to 
yield a clinically viable nNOS inhibitor in the near future, 
which could significantly improve the quality of life for 
those suffering from debilitating illness.  
ABBREVIATIONS 
BBB = Blood brain barrier 
CMR = Calculated molar refractivity 
CaM = Calmodulin 
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CBR = Calmodulin binding region 
CNS = Central nervous system 
CoMFA = Comparative molecular field analysis 
CoMSIA = Comparative molecular similarity index analysis 
CPCA = Consensus principal component analysis 
cGMP = Cyclic guanosine 3’,5’-monophosphate 
eNOS = Endothelial nitric oxide synthase 
FAD = Flavin adenine dinucleotide 
FMN = Flavin mononucleotide 
HB = Hydrogen bond 
HBA = Hydrogen bond acceptor 
HBD = Hydrogen bond donor 
iNOS = Inducible nitric oxide synthase 
LBDD = Ligand based drug design 
MD = Molecular dynamics 
NADPH = Nicotinamide adenine dinucleotide phosphate 
nNOS = Neuronal nitric oxide synthase 
L-NNA = Nω-nitro-L-arginine 
L-NOHA = N-hydroxy-L-arginine 
NO = Nitric oxide 
NOS = Nitric oxide synthase 
NMR = Nuclear magnetic resonance 
PK = Pharmacokinetics 
Por = Porphyrin 
QSAR = Quantitative structure activity relationship 
RNS = Reactive nitrogen species 
ROS = Reactive oxygen species 
RPI = Relative permeability index 
SMD = Steered molecular dynamics 
SBDD = Structure based drug design 
BH4 = Tetrahydrobiopterin 
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